2 November warning letters put FDA ad police on cusp of double-digit reprimands for 2019

FDA Building
The FDA's prescription drug promo policing unit, the Office of Prescription Drug Promotion, dinged two misleading pharma websites last month. (FDA)

The FDA's ad watchdog, the Office of Prescription Drug Promotion (OPDP), sent untitled letters to Nascent Biotech and Rockwell Medical in November, bringing the total issued for the year to nine. That’s already an uptick from last year’s seven letters and five total for 2017.

The first letter last month went to Nascent Biotech regarding its investigational cancer drug pritumumab. OPDP dinged the biotech for its website, on which Nascent promoted the drug as safe and effective even though it has not yet been approved.

RELATED: Déjà vu? Galt's insomnia drug Doral gets 2nd wrist slap from FDA promo police


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

The agency took issue with some of Nascent’s statements, including, “Pritumumab has cured a rare form of brain cancer” and, “After 5 years, patients treated with pritumumab have an overall survival rate of 25-30%, compared to 3% standard therapy, demonstrating antibodies are safe and effective.”

OPDP’s letter says the cure statement is “especially troubling given that brain cancer in general is a disease associated with a poor prognosis.”

The second letter went to Rockwell Medical regarding its iron replacement product Triferic and misleading webpage information. OPDP says that the Rockwell digital site included the benefits of the drug but “fails to include any risk information.”

RELATED: Pharma ad police issues 2019's first warning over promotion of unapproved imaging drug

The agency also disputes several claims on the website that mislead by suggesting Triferic is safer and more effective than other IV iron replacement products, which has not been shown. Comparing the FDA’s snapshot of the misleading pages with Rockwell’s current information, the page is now changed with the named claims removed.

OPDP’s nine letters in 2019 is no record—that would be the 156 letters sent in 1998—but rather is a modest increase, keeping pace with the past few years.

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.